FATE - Fate Therapeutics, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 605.95M
Enterprise value 304.67M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.35
Price/book (mrq)1.28
Enterprise value/revenue 2.23
Enterprise value/EBITDA -1.23

Trading information

Stock price history

Beta (5Y monthly) 1.49
52-week change 3-77.79%
S&P500 52-week change 31.77%
52-week high 337.13
52-week low 34.02
50-day moving average 35.62
200-day moving average 313.77

Share statistics

Avg vol (3-month) 32.65M
Avg vol (10-day) 31.93M
Shares outstanding 598.38M
Implied shares outstanding 6N/A
Float 883.7M
% held by insiders 11.51%
% held by institutions 1106.35%
Shares short (14 May 2023) 429.13M
Short ratio (14 May 2023) 412.45
Short % of float (14 May 2023) 437.98%
Short % of shares outstanding (14 May 2023) 429.61%
Shares short (prior month 13 Apr 2023) 426.92M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin -171.64%
Operating margin (ttm)-191.80%

Management effectiveness

Return on assets (ttm)-22.04%
Return on equity (ttm)-42.29%

Income statement

Revenue (ttm)136.87M
Revenue per share (ttm)1.41
Quarterly revenue growth (yoy)220.30%
Gross profit (ttm)-224.15M
EBITDA -247.32M
Net income avi to common (ttm)-234.91M
Diluted EPS (ttm)-2.32
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)408.9M
Total cash per share (mrq)4.16
Total debt (mrq)107.61M
Total debt/equity (mrq)22.54
Current ratio (mrq)9.00
Book value per share (mrq)4.86

Cash flow statement

Operating cash flow (ttm)-212.46M
Levered free cash flow (ttm)-131.32M